reading MASH threads from 2024 and half of it aged badly
Long-ish post, sorry. tl;dr at the bottom. I have been tracking survodutide against triglycerides for 31 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one…
Yeah, glucagon co-agonism is genuinely different.
Removed a chain here. The rule is one line long and it is not negotiable.
Came off after 89 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.
the MASH indication changes the risk calculus